Adjusting forecast for the current fiscal year – Biotech Investments

MeVis Medical Solutions AG / Key word(s): Change in Forecast

MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year

04-Sep-2024 / 17:39 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Bremen, September 4, 2024 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, is adjusting its annual forecast for the current fiscal year based on the preliminary business figures for the first eleven months.

  • For fiscal year 2023/2024 (October 1, 2023 to September 30, 2024), sales are now expected to remain stable at between € 17.0 million and € 17.5 million (previous forecast for fiscal year 2023/2024: slight increase in sales from € 18.0 million to € 18.5 million).
  • EBIT (earnings before interest and taxes) is now expected to fall to between € 3.0 million and € 3.5 million in fiscal year 2023/2024 (October 1, 2023 to September 30, 2024) (previous forecast for fiscal year 2023/2024: stability in the range of € 4.5 million to € 5.0 million).

The reasons for the decline in sales are an unexpected cautiousness in purchasing behavior due to global economic challenges. In addition, the result will be strongly impacted by the development of the US dollar/euro exchange rate since the beginning of the fiscal year.

************************************************************************

Contact:
Kirchhoff, Marcus / CEO

End of Inside Information


04-Sep-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this